Astellas Institute for Regenerative Medicine
Clinical trials sponsored by Astellas Institute for Regenerative Medicine, explained in plain language.
Research arm of Astellas Pharma focused on regenerative medicine.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Can stem cells restore vision in stargardt disease? a First-in-Human trial aims to find out
Cure Recruiting nowThis early-phase trial tests a single injection of ASP2020, stem cells turned into retinal cells, placed under the retina in people with Stargardt disease or similar inherited macular dystrophies. The main goal is to check safety and tolerability, while also looking for signs tha…
Phase 1 • Sponsor: Astellas Institute for Regenerative Medicine • Aim: Cure
Last updated Aug 29, 2026 00:00 UTC
-
Stem cell injection aims to restore vision in dry AMD patients
Disease control Recruiting nowThis early-stage study tests a stem cell therapy called ASP7317 for people with geographic atrophy, the advanced form of dry age-related macular degeneration that causes central vision loss. The treatment involves injecting special cells under the retina to replace damaged ones. …
Phase 1 • Sponsor: Astellas Institute for Regenerative Medicine • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC